Merck's Guardant Liquid Biopsy Alliance: Impact on Investment Case

Merck has partnered with Guardant Health to use its liquid and tissue biopsy platform for clinical trials, companion diagnostics, and commercialization efforts. This collaboration highlights Merck's focus on advanced molecular diagnostics to strengthen clinical development and personalize cancer treatment decisions. The partnership may support Merck's long-term growth story and risk profile, but it does not change the nearer-term focus on upcoming trial readouts and regulatory decisions. Merck's revenue and earnings forecasts by 2028 require 4.2% yearly revenue growth and an earnings increase of about $7.9 billion.